Clinigen Group plc Director/PDMR Shareholding (9936M)
September 19 2019 - 7:37AM
UK Regulatory
TIDMCLIN
RNS Number : 9936M
Clinigen Group plc
19 September 2019
19 September 2019
CLINIGEN GROUP PLC
PDMR SHAREHOLDINGS
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company')
announces the following PDMR dealings in accordance with Article 19
of the Market Abuse Regulation:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Nick Keher
--------------------- ------------------------------------
2 Reason for the notification
-----------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------- ------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
-----------------------------------------------------------
a) Name Clinigen Group plc
--------------------- ------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
--------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
-----------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
--------------------- ------------------------------------
b) Nature of the Purchase of shares
transaction
--------------------- ------------------------------------
c) Currency GBP
--------------------- ------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------- ------------------- ---------------
893p per share 3,900 shares
--------------------- ------------------- ---------------
e) Aggregated 3,900 shares
information 893p
- Aggregated GBP34,827
volume
- Price
- Aggregated
total
--------------------- ------------------------------------
f) Date of the 19 September 2019
transaction
--------------------- ------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------- ------------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283 495
010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260 1000
& Joint Broker
James Black / Freddie Barnfield / Freddie
Naylor-Leyland
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell
/ Rozi Morris Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in
14 countries, with supply and distribution hubs and operational
centres of excellence in key long-term growth regions. The Group
works with 22 of the top 25 pharmaceutical companies; interacting
with over 15,000 registered users across over 100 countries,
shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit
www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFVLAEIALIA
(END) Dow Jones Newswires
September 19, 2019 07:37 ET (11:37 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024